https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/la-musica-del-cuore-in-calabria-giornata-di-screening-gratuiti-della-fibrillazione-atriale/ 2019-08-07T15:30:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-il-follow-up-a-quattro-anni-rafforza-la-consistente-efficacia-e-sicurezza-del-trattamento-con-edoxaban/ 2023-08-28T15:36:52+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/gli-studi-destiny-breast05-e-destiny-breast11-presentati-al-presidential-symposium-di-esmo-rafforzano-il-potenziale-di-trastuzumab-deruxtecan-di-diventare-un-trattamento-fondamentale-nel-setting-del-tumore-al-seno-in-fase-iniziale-con-finalita-curativa/ 2025-10-21T15:37:07+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/leucemia-mieloide-acuta-la-monoterapia-con-quizartinib-prolunga-significativamente-la-sopravvivenza/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-lacido-bempedoico-riduce-significativamente-il-rischio-di-eventi-cardiovascolari-totali-e-non-provoca-aumento-della-glicemia-o-dellincidenza-di-diabete-di-nuova-insorgenza-in-pazienti-ad-alto-rischio-di-malattie-cardiovascolari/ 2023-08-28T15:35:54+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tromboembolismo-venoso-tev-i-dati-real-world-mostrano-bassa-incidenza-di-emorragie-e-di-recidive-in-12-mesi-di-trattamento-con-edoxaban/ 2020-07-14T17:11:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-metastatico-triplo-negativo-studio-di-fase-3-tropion-breast02-datopotamab-deruxtecan-ha-migliorato-significativamente-la-sopravvivenza-globale-mediana-di-cinque-mesi-rispetto-alla-chemioterapia-per-il-trattamento-di-prima-linea-di-pazien/ 2025-10-21T15:37:12+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tromboembolismo-venoso-acuto-edoxaban-lixiana-efficace-e-sicuro-anche-a-dosaggio-ridotto-per-pazi/ 2016-09-30T12:00:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/le-note-del-cuorebattono-per-lafrica-cardiologi-musicisti-in-concerto-per-il-cuore-dei-bimbi-afr/ 2019-08-07T15:30:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/un-think-tank-europeo-multidisciplinare-per-migliorare-lapproccio-olistico-alle-cure-cardiovascolari/ 2024-05-27T09:15:41+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-metastatico-lfda-ha-designato-trastuzumab-deruxtecan-come-breakthrough-therapy-per-il-carcinoma-mammario-a-bassi-livelli-di-espressione-her2-her2low/ 2022-05-06T14:34:50+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/world-conference-on-lung-cancer-wclc2021-cancro-al-polmone-trastuzumab-deruxtecan-enhertu-r-evidenzia-una-promettente-attivita-antitumorale-anche-nei-pazienti-con-carcinoma-nsclc-avanzato/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/terapia-anticoagulante-con-lixianar-meno-emorragie-intracraniche-rispetto-al-warfarin/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-her2-metastatico-fda-approva-trastuzumab-deruxtecan-per-le-pazienti-precedentemente-trattate-con-una-terapia-a-base-di-anti-her2/ 2022-05-06T14:34:34+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/nello-studio-di-fase-3-tropion-lung-01-datopotamab-deruxtecan-mostra-un-miglioramento-clinicamente-significativo-della-sopravvivenza-globale-nei-pazienti-con-carcinoma-polmonare-non-a-piccole-cellule-ad-istologia-non-squamosa-in-stadio-avanzato/ 2024-05-29T11:33:19+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/il-covid-19-aumenta-i-rischi-per-il-cuore-un-nuovo-studio-delleconomist-impact-conferma-lurgenza-di-tornare-a-concentrarsi-sulla-salute-cardiovascolare/ 2022-05-10T12:21:12+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-fa-una-maggiore-appropriatezza-prescrittiva-delle-terapie-anticoagulanti-ga/ 2016-12-02T09:02:54+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-internazionale-delle-donne-medicina-di-genere-daiichi-sankyo-e-onda-supportano-la-formazione-dei-medici-per-una-cardiologia-al-femminile/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-lacido-bempedoico-ha-ridotto-il-rischio-di-eventi-cardiovascolari-avversi-maggiori-in-vari-sottogruppi-di-pazienti-nuove-analisi-dei-dati-clear-outcomes/ 2024-05-30T09:52:58+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/medicina-e-solidarieta-un-libro-fotografico-per-dare-speranza-ai-bambini-cardiopatici-del-mondo/ 2016-12-13T17:15:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tromboembolia-venosa-edoxaban-lixiana-efficace-e-sicuro-anche-per-i-pazienti-a-piu-alto-rischio/ 2016-12-19T08:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2022-fibrillazione-atriale-in-pazienti-complessi-edoxaban-efficace-e-sicuro-anche-nei-pazienti-fa-con-fragilita-diabete-mellito-e-insufficienza-cardiaca-i-dati-del-registro-etna-af/ 2022-08-30T09:08:27+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-i-pazienti-diabetici-che-richiedono-insulina-presentano-un-aumentato-rischio/ 2017-01-31T08:30:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2022-ipercolesterolemia-con-laggiunta-di-acido-bempedoico-al-trattamento-ipolipemizzante-piu-pazienti-ad-alto-e-altissimo-rischio-potrebbero-raggiungere-gli-obiettivi-di-c-ldl-nuovi-dati-dallo-studio-santorini/ 2022-08-30T09:07:06+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-tenosinoviale-a-cellule-giganti-pexidartinib-di-daiichi-sankyo-ne-riduce-significativamente/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-arruolato-il-primo-paziente-di-entrust-af-pci-lo-studio-daiichi-sankyo-in-pa/ 2017-05-03T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-eha-leucemia-mieloide-acuta-il-quizartinib-riduce-del-24-il-rischio-di-morte-e-aumenta/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/battiti-2017-la-musica-col-cuore-medici-musicisti-di-nuovo-insieme-sul-palco-contro-ic/ 2019-08-07T15:30:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ricerca-scientifica-selezionate-le-rising-stars-tra-i-talenti-italiani-under-40/ 2018-06-20T08:52:41+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-metastatico-her2-positivo-trastuzumab-deruxtecan-e-rimborsato-in-italia-quadruplica-la-sopravvivenza-libera-da-progressione/ 2023-09-12T12:50:41+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/quizartinib-disponibile-in-italia-per-i-pazienti-con-leucemia-mieloide-acuta-flt3-itd-positiva-di-nuova-diagnosi/ 2025-11-24T17:19:11+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/cardiobreast-dragon-boat-festival-a-milano-e-roma-si-rema-insieme-contro-il-tumore-al-seno-e-le-malattie-cardiovascolari/ 2022-09-13T17:35:21+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/trastuzumab-deruxtecan-vince-il-prestigioso-prix-galien-per-il-miglior-prodotto-chimico-biotecnologico/ 2024-09-12T08:51:04+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-e-pazienti-ad-alto-rischio-nuovi-studi-su-lixiana-edoxaban-nel-trattamento/ 2017-05-03T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2018-aderenza-e-terapie-doac-presentata-la-nuova-confezione-di-lixianar-per-assicura/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/sport-cancro-e-cuore-le-pagaiatrici-in-rosa-si-sfidano-nella-terza-edizione-del-cardiobreast-dragon-boat-festival-la-prima-tappa-2024-a-roma/ 2024-07-17T11:22:15+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-ehra-2021-fibrillazione-atriale-dati-real-world-aggiornati-da-etna-af-europe-riaffermano-i-benefici-di-lixianar-edoxaban-nelle-persone-di-tutte-le-eta/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/affrontare-il-tumore-al-seno-e-le-malattie-cardiovascolari-a-colpi-di-pagaia-torna-il-cardiobreast-dragon-boat-festival/ 2023-11-20T12:40:42+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumori-femminili-prevenzione-e-ricerca-le-chiavi-di-un-futuro-in-rosa/ 2017-06-21T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2018-combattere-la-fibrillazione-atriale-nel-mondo-reale-presentati-i-primi-dati-d/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ottobre-rosa-pazienti-atlete-pagaiano-a-roma-nellultima-tappa-del-cardiobreast-dragon-boat-festival/ 2022-10-13T09:29:42+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-lacido-bempedoico-nilemdor-conferma-una-significativa-riduzione-del-colesterolo-se-aggiunto-alle-statine-per-25-anni-di-trattamento-lestensione-del-trial-clear-harmony-presentato-allesc/ 2020-08-28T10:29:51+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-lixianar-riceve-parere-positivo-dal-chmp-dellema-per-lutilizzo-in-pazienti/ 2017-07-17T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-non-valvolare-lixianar-edoxaban-efficace-e-sicuro-nei-pazienti-anziani-i-dati-real-world-del-registro-etna-af/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-presenta-i-dati-aggiornati-sufam-trastuzumab-deruxtecan-in-pazienti-con-carcinoma/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-e-diabete-di-tipo-2-primi-risultati-positivi-per-lassociazione-fissa-di-acido-bempedoico-ezetimibe/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-e-insufficienza-renale-bassa-incidenza-di-sanguinamenti-ed-emorragie-intracraniche-in-pazienti-fragili-e-anziani-con-fa-in-terapia-con-lixianar-edoxaban-allesc-nuovi-dati-da-etna-af/ 2020-08-31T11:04:19+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/malattie-cardiovascolari-le-disuguaglianze-di-genere-e-la-mancata-aderenza-terapeutica-impattano-sugli-esiti-clinici-dei-pazienti-limpegno-di-daiichi-sankyo-nel-ridurre-i-gap-con-studi-e-approcci-olistici-alla-cura/ 2024-09-04T09:04:22+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fa-e-impianto-stent-daiichi-sankyo-presenta-i-risultati-positivi-di-entrust-af-pci-lo-studio-su-lixianar-edoxaban-in-pazienti-con-fa-sottoposti-a-intervento-coronarico-percutaneo/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-del-cuore-ad-aprilia-giornata-di-screening-gratuiti-della-fibrillazione-atriale/ 2018-10-04T12:29:39+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/conferenza-mondiale-sul-cancro-al-polmone-2019-ladc-u3-1402-di-daiichi-sankyo-ha-confermato-la-riduzione-delle-dimensioni-del-tumore-in-pazienti-con-carcinoma-polmonare-non-a-piccole-cellule-con-egfr-mutato-i-dati-aggiornati-presentati-a-barcellona/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-trastuzumab-deruxtecan-mostra-unattivita-clinica-consistente-nelle-pazienti-con-malattia-metastatica-her2-positiva-e-metastasi-cerebrali/ 2024-09-17T10:49:53+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esmo-2024-il-nuovo-adc-ds-9606-di-daiichi-sankyo-mostra-una-promettente-attivita-clinica-preliminare-in-pazienti-con-tumori-solidi-avanzati/ 2024-09-17T10:53:48+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/conferenza-mondiale-sul-cancro-al-polmone-2019-farmaci-anticorpo-coniugati-daiichi-sankyo-presenta-i-dati-promettenti-di-ds-1062-per-pazienti-con-carcinoma-polmonare-non-a-piccole-cellule-ad-uno-stadio-avanzato/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/i-dipendenti-di-daiichi-sankyo-italia-insieme-per-dare-sostegno-alle-comunita-dellemilia-romagna-colpite-dallalluvione/ 2023-09-27T10:37:49+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/il-tuo-cuore-nelle-tue-mani-arriva-a-torino-la-campagna-per-la-prevenzione-cardio-cerebrovascolare-con-screening-gratuiti/ 2026-01-22T10:24:51+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-risultati-finali-della-coorte-tedesca-dello-studio-milos-mostrano-che-lacido-bempedoico-riduce-significativamente-il-c-ldl/ 2024-09-27T08:50:54+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/mycancertherapyeu-daiichi-sankyo-presenta-il-nuovo-sito-web-che-risponde-ai-dubbi-dei-pazienti-onc/ 2023-11-20T11:31:36+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/terapie-piu-sicure-nuove-tecnologie-e-supporto-ai-caregiver-per-migliorare-la-qualita-di-vita-degli-anziani/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-della-societa-europea-di-oncologia-medica-esmo-breast-2021-carcinoma-mammario-triplo-negativo-metastatico-i-dati-sulladc-datopotamab-deruxtecan-mostrano-una-risposta-preliminare-e-un-controllo-della-malattia-promettenti/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-lipertensione-arteriosa-2014/ 2016-03-18T07:49:32+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2017-ictus-e-fibrillazione-atriale-anche-nei-pazienti-a-piu-alto-rischio-lixianar-e/ 2017-10-04T10:04:05+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tromboembolismo-venoso-e-allarme-in-europa-le-donne-i-soggetti-piu-a-rischio-prevenire-e-indis/ 2016-03-18T07:52:04+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-nazionale-della-prevenzione-cardiovascolare-vicini-di-colesterolo-le-divertenti-vicissitudini-di-un-condominio-italiano-insegnano-a-prevenire-e-gestire-lipercolesterolemia-presto-anche-su-amazon-prime-video/ 2021-05-12T07:44:11+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-polmonare-non-a-piccole-cellule-nsclc-datopotamab-deruxtecan-migliora-la-sopravvivenza-libera-da-progressione-rispetto-alla-chemioterapia-in-pazienti-precedentemente-trattati-i-risultati-dello-studio-di-fase-3-tropion-lung01/ 2023-10-24T10:24:49+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-e-feder-aipa-mettono-in-guardia-contro-i-pericoli-della-fibrillazione-atriale/ 2016-04-01T11:35:40+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-daiichi-sankyo-estende-il-registro-europeo-prefer-in-af-ad-altri-5000-pazienti/ 2016-04-25T16:47:53+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-e-cardioversione-arruolato-il-primo-paziente-di-ensure-af-il-nuovo-trial-cli/ 2016-03-18T07:45:12+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/festa-dei-nonni-2019-piu-la-vita-ti-segna-piu-valore-ha-mostra-audio-visiva-e-screening-gratuito-della-fibrillazione-atriale-per-riconoscere-lesperienza-e-il-valore-delle-persone-anziane/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/datopotamab-deruxtecan-prolunga-significativamente-la-sopravvivenza-libera-da-progressione-rispetto-alla-chemioterapia-in-pazienti-con-carcinoma-mammario-hr-positivo-her2-low-o-negativo-i-risultati-dello-studio-di-fase3-tropion-breast01/ 2023-10-24T12:46:48+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-negli-anziani-con-lixianar-edoxaban-bassa-incidenza-di-emorragie-e-di-eventi-cardiovascolari-i-dati-real-world-ad-un-anno-di-follow-up-del-registro-etna-af-europe-presentati-a-pechino/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esh-ish-2014-delineati-nuovi-schemi-terapeutici-per-guidare-i-medici-nella-gestione-dei-p/ 2016-03-17T16:44:38+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/leucemia-mieloide-acuta-recidivanterefrattaria-con-mutazioni-di-flt3-itd-lema-concede-la-valutazi/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/piu-la-vita-ti-segna-piu-valore-ha-daiichi-sankyo-include-anche-i-suoi-dipendenti-nella-campagna-di-sensibilizzazione-su-invecchiamento-attivo-e-supporto-ai-caregiver/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-la-fibrillazione-atriale-2017-e-a-suon-di-bonghi-la-lotta-allaritmia-da/ 2017-10-04T10:03:49+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/un-flash-mob-per-liberare-la-circolazione-dal-colesterolo-e-ricordare-che-il-controllo-del-rischio-cardiovascolare-dipende-da-noi/ 2024-10-01T09:02:22+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/il-tuo-cuore-nelle-tue-mani-arriva-a-palermo-la-campagna-per-la-prevenzione-cardio-cerebrovascolare-con-screening-gratuiti/ 2026-03-12T12:40:17+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/medicina-di-genere-e-gestione-dellaggressivita-punti-fondamentali-per-la-sicurezza-e-la-salute-del/ 2018-11-19T17:54:06+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-asco-2021-carcinoma-polmonare-non-a-piccole-cellule-avanzato-lanti-her3-patritumab-deruxtecan-di-daiichi-sankyo-dimostra-efficacia-in-termini-di-risposte-su-meccanismi-multipli-di-resistenza-in-pazienti-con-mutazione-egfr/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/correlazione-cancro-trombosi-frequente-potenzialmente-fatale-ma-spesso-sconosciuta-ai-pazienti/ 2018-11-19T17:55:16+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/lacido-bempedoico-riduce-significativamente-il-colesterolo-ldl-in-aggiunta-alla-terapia-con-statine-i-risultati-del-trial-clear-wisdom-pubblicati-sul-jama/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/piu-la-vita-ti-segna-piu-valore-ha-a-milano-la-seconda-tappa-dello-screening-gratuito-della-fibrillazione-atriale-con-la-mostra-audio-visiva-di-daiichi-sankyo-che-celebra-il-valore-delle-persone-anziane/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/aha-scientific-sessions-2019-lacido-bempedoico-riduce-il-colesterolo-senza-influenzare-negativamente-il-controllo-glicemico-i-risultati-di-analisi-combinate-presentati-al-congresso-aha/ 2019-12-12T15:30:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/al-via-cardio-hub-il-laboratorio-permanente-di-idee-e-progettualita-condivise-per-migliorare-la-qualita-di-vita-delle-persone-con-malattie-cardio-cerebrovascolari/ 2026-03-25T09:15:18+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/san-antonio-breast-cancer-symposium-2019-carcinoma-mammario-metastatico-her2-positivo-la-risposta-del-tumore-al-ds-8201-fam-trastuzumab-deruxtecan-ha-raggiunto-il-609-nello-studio-destiny-breast01/ 2019-12-16T12:26:02+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ottobre-rosa-le-breast-cancer-paddlers-si-sfidano-a-firenze-nella-terza-tappa-del-cardiobreast-dragon-boat-festival/ 2024-10-17T15:36:45+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/prevenzione-cardiovascolare-durante-e-dopo-la-pandemia-tornano-a-esibirsi-in-teatro-i-cardiologi-musicisti-con-3-cuori-per-la-musica-ricominciare-e-poi/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-ash-2018-leucemia-mieloide-acuta-quizartinib-aumenta-la-sopravvivenza-complessiva-nei-pa/ 2018-12-04T08:46:29+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-mammario-her2-metastatico-con-trastuzumab-deruxtecan-t-dxd-raggiunta-la-significativita-statistica-per-il-dato-di-sopravvivenza-globale-con-una-riduzione-del-rischio-di-morte-del-36-rispetto-a-trastuzumab-emtansine-t-dm1/ 2022-12-13T09:30:31+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/a-palermo-la-penultima-tappa-del-cardiobreast-dragon-boat-festival-2024-per-lottobre-rosa/ 2024-10-24T12:07:57+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esmo-2020-carcinomi-polmonari-e-anticorpi-monoclonali-coniugati-adc-daiichi-sankyo-ha-presentato-i-risultati-di-fase-i-di-patritumab-deruxtecan-u3-1402-in-pazienti-con-carcinoma-polmonare-non-a-piccole-cellule-con-egfr-mutato/ 2020-09-18T08:40:15+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/le-donne-italiane-sottovalutano-il-proprio-rischio-cardiovascolare-e-credono-ancora-che-sia-un-fenomeno-prettamente-maschile/ 2024-10-28T10:22:24+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-gastrico-avanzato-her2-per-enhertu-trastuzumab-deruxtecan-inizia-lo-studio-testa-a-testa-di-fase-3-destiny-gastric04/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-mammario-her2-positivo-non-operabile-o-metastatico-fda-approva-enhertur-ds8201-o-trastuzumab-deruxtecan-per-la-malattia-che-progredisce-dopo-due-o-piu-terapie-anti-her2/ 2019-12-23T10:00:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-lacido-bempedoico-mostra-una-riduzione-statisticamente-significativa-del-rischio-relativo-di-eventi-avversi-cardiovascolari-maggiori-endpoint-primario-raggiunto-nello-studio-clear-outcomes/ 2022-12-13T09:31:31+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-sic-2018-primi-dati-di-real-life-sullutilizzo-di-edoxaban-dal-registro-etna-af-in-itali/ 2018-12-14T09:25:00+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2021-nuovi-dati-supportano-luso-di-lixianar-edoxaban-in-pazienti-complessi-con-fibrillazione-atriale-fa/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2021-ipercolesterolemia-in-europa-nei-pazienti-a-rischio-alto-e-molto-alto-livelli-di-c-ldl-ancora-troppo-elevati-e-terapie-di-combinazione-sottoutilizzate-lo-studio-osservazionale-europeo-santorini/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/cardiocompass-la-nuova-app-daiichi-sankyo-per-aumentare-la-consapevolezza-sul-rischio-cardio-cerebrovascolare/ 2026-05-08T09:16:03+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-gastrico-avanzato-her2-il-chmp-raccomanda-lapprovazione-in-ue-di-trastuzumab-deruxtecan-per-pazienti-pretrattati/ 2023-11-20T12:43:57+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-europe-esperion-accordo-per-la-commercializzazione-in-europa-di-acido-bempedoicoe/ 2019-01-08T09:24:25+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ottobre-mese-della-prevenzione-del-cancro-al-seno-daiichi-sankyo-presenta-pink-positive-lebook-gratuito-scritto-dagli-specialisti-per-le-donne-che-affrontano-il-cancro/ 2020-10-05T10:51:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-la-fibrillazione-atriale-2014/ 2016-04-25T16:44:22+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-edoxaban-a-dosaggio-ridotto-efficace-anche-nei-pazienti-a-piu-alto-rischio/ 2016-05-31T10:40:34+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/colesterolo-ldl-lacido-bempedoico-nilemdor-riduce-significativamente-il-colesterolo-nei-pazienti-con-ipercolesterolemia-familiare-lanalisi-presentata-alleas2020/ 2020-10-08T08:44:31+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-gastrico-avanzato-her2-trastuzumab-deruxtecan-approvato-in-ue-per-pazienti-pretrattati-e-il-primo-anti-her2-in-10-anni-ad-essere-approvato-in-europa-per-questa-indicazione/ 2022-12-22T08:28:20+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-lictus-2014-i-cardiologi-chiedono-maggior-prevenzione-lavoro-di-sq/ 2016-03-17T16:23:30+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-della-societa-europea-di-oncologia-medica-esmo-2021-carcinoma-gastrico-avanzato-her2-trastuzumab-deruxtecan-ha-dimostrato-una-risposta-clinicamente-significativa-e-duratura-nei-pazienti-dello-studio-di-fase-2-destiny-gastric02/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-della-societa-europea-di-oncologia-medica-esmo-2021-cancro-al-polmone-trastuzumab-deruxtecan-ha-dimostrato-una-risposta-tumorale-robusta-e-duratura-nel-549-dei-pazienti-con-carcinoma-polmonare-non-a-piccole-cellule-metastatico-con-mutazion/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-mammario-her2-positivo-e-adc-daiichi-sankyo-e-astrazeneca-sperimentano-enhertur-anche-come-terapia-adiuvante-per-pazienti-in-stadio-iniziale-ma-ad-alto-rischio-di-recidiva/ 2020-11-03T08:27:27+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-della-societa-europea-di-oncologia-medica-esmo-2021-carcinoma-mammario-metastatico-her2-trastuzumab-deruxtecan-ha-ridotto-il-rischio-di-progressione-della-malattia-del-72-rispetto-a-trastuzumab-emtansine-t-dm1/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-della-societa-europea-di-oncologia-medica-esmo-2021-cancro-al-polmone-ladc-datopotamab-deruxtecan-dimostra-una-risposta-tumorale-incoraggiante-nei-pazienti-con-carcinoma-polmonare-non-a-piccole-cellule-avanzato-con-alterazioni-genomiche-se/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-lictus-2017-ictus-conoscerlo-per-prevenirlo-iniziativa-di-screening-g/ 2017-10-20T12:20:33+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-crea-la-nuova-business-unit-oncology-per-unificare-i-principali-mercati-di-usa-ed-europa-in-ununica-organizzazione-dedicata-ai-pazienti-oncologici/ 2020-11-13T09:55:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/medicina-e-solidarieta-una-unita-di-cardiochirurgia-allavanguardia-in-senegal-per-dare-speranz/ 2016-04-25T16:43:50+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-ulteriori-dati-dimostrano-i-benefici-dellacido-bempedoico-daiichi-sankyo-presenta-i-risultati-al-congresso-acc-che-si-e-svolto-in-streaming-congiuntamente-al-congresso-internazionale-di-cardiologia-acc20-wcc/ 2020-07-14T17:11:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/trastuzumab-deruxtecan-approvato-in-ue-come-prima-terapia-anti-her2-per-pazienti-con-tumore-al-seno-metastatico-con-bassi-livelli-di-espressione-di-her2-her2-low/ 2023-01-31T19:08:16+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/colesterolo-ldl-e-differenze-di-genere-lacido-bempedoico-riduce-significativamente-il-colesterolo-in-entrambi-i-sessi-con-percentuali-maggiori-nelle-donne-i-risultati-presentati-da-daiichi-sankyo-allaha-2020/ 2020-11-17T08:14:48+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/colesterolo-ldl-lema-convalida-la-richiesta-di-immissione-in-commercio-dellacido-bempedoico-e-della-sua-associazione-fissa-con-ezetimibe/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/stili-di-vita-al-centro-del-percorso-di-cura-il-progetto-pink-positive-si-arricchisce-con-podcast-su-nutrizione-e-musicoterapia-e-servizi-per-le-pazienti-che-affrontano-il-cancro/ 2023-02-02T08:54:25+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-ehra-2019-bassa-frequenza-di-eventi-tromboembolici-ed-emorragici-con-luso-peri-procedurale-di-edoxaban-lixianar-in-pazienti-anziani-con-fa-tev-sottoposti-a-procedure-diagnostiche-e-terapeutiche/ 2019-05-28T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-in-europa-necessario-affrontare-la-percezione-e-la-classificazione-del-rischio-cardiovascolare-gli-ultimi-dati-dello-studio-santorini-presentati-al-congresso-eas-2022/ 2022-06-06T09:27:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/il-cuore-della-musica-a-roma-i-cardiologi-musicisti-di-nuovo-in-concerto-per-la-lotta-alla-morte-cardiaca-improvvisa/ 2019-10-15T11:12:16+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/salute-delle-donne-un-investimento-sociale-ed-economico-e-un-obiettivo-strategico-per-la-sanita/ 2025-03-31T17:12:34+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/menu-del-giorno-la-salute-del-cuore-i-consigli-degli-esperti-europei-e-di-chef-ruben-bondi-per-i-pazienti-affetti-da-fibrillazione-atriale-nellevento-beats-and-bits-di-daiichi-sankyo-europe/ 2025-03-12T11:43:46+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-rapporto-economist-impact-litalia-si-distingue-per-accesso-e-rimborsabilita-delle-terapie-ma-prevenzione-e-screening-ancora-sotto-la-soglia-minima-raccomandata-in-europa/ 2025-03-28T08:56:53+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-asco-2019-carcinoma-polmonare-non-a-piccole-cellule-con-egfr-mutato-riduzione-delle-dimensioni-del-tumore-nei-dati-preliminari-dello-studio-di-fase-i-sul-nuovo-farmaco-anticorpo-coniugato-di-daiichi-sankyo-u3-1402/ 2019-08-07T15:30:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-approvati-in-europa-linnovativo-trattamento-ipolipemizzante-nilemdor-acido-bempedoico-e-la-sua-associazione-con-ezetimibe-nustendir/ 2020-07-14T17:11:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-aifa-approva-la-rimborsabilita-per-il-nuovo-trattamento-first-in-class-di-acido-bempedoico-e-dellassociazione-fissa-acido-bempedoico-ezetimibe/ 2023-11-20T12:43:36+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-metastatico-her2-low-aifa-approva-la-rimborsabilita-di-trastuzumab-deruxtecan-riduce-il-rischio-di-progressione-della-malattia-o-di-morte-del-50/ 2024-01-09T14:16:11+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-lfda-designa-trastuzumab-deruxtecan-come-breakthrough-therapy-per-le-pazienti-con-carcinoma-mammario-her2-precedentemente-trattate-con-uno-o-piu-anti-her2/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/covid-19-e-cuore-un-portale-per-supportare-gli-specialisti-nella-cura-dei-cardiopatici-affetti-da-covid-19/ 2020-07-14T17:11:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ottobre-mese-della-prevenzione-del-cancro-al-seno-sana-alimentazione-e-stile-di-vita-attivo-per-ridurre-il-rischio-di-recidive-i-consigli-della-scienza-su-pinkpositiveit-e-le-iniziative-di-daiichi-sankyo-per-sensibilizzare-i-suoi-dipendenti-grazie-al/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/mercoledi-a-roma-screening-cardiologici-gratuiti-offerti-dalla-croce-rossa-per-le-giornate-dedicate-alla-prevenzione-cardiovascolare-del-donatore-di-sangue/ 2023-04-14T09:23:43+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/al-via-metalab-primo-laboratorio-di-idee-progetti-e-proposte-per-rispondere-ai-bisogni-di-cura-dei-pazienti-con-tumori-metastatici/ 2025-03-28T12:38:06+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/dopo-tokyo-e-washington-anche-roma-festeggia-lhanami-con-nuovi-ciliegi-alla-passeggiata-del-gia/ 2016-04-25T16:43:16+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ictus-e-fibrillazione-atriale-non-valvolare-edoxaban-arriva-anche-in-europa-con-lapprovazione-di/ 2016-05-31T10:49:21+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/riduzione-significativa-del-colesterolo-ldl-con-associazione-fissa-acido-bempedoico-ezetimibe-le-evidenze-pubblicate-su-european-journal-of-preventive-cardiology/ 2019-08-28T09:30:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ictus-e-tromboembolismo-venoso-il-nuovo-anticoagulante-orale-edoxaban-riceve-parere-positivo-dal-co/ 2016-05-31T10:48:51+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/burodriver-per-i-medici-la-burocrazia-non-e-mai-stata-cosi-facile/ 2016-03-17T16:10:54+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-lictus-cerebrale-2021-entra-nel-vivo-il-progetto-value-based-healthcare-ecosystem-per-una-gestione-innovativa-ed-efficiente-dei-pazienti-cronici-a-rischio-cardiovascolare-prima-e-fuori-dallospedale/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-lipertensione-arteriosa-2015/ 2016-04-25T16:39:44+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/trastuzumab-deruxtecan-riduce-il-rischio-di-progressione-della-malattia-o-di-morte-del-50-rispetto-alla-chemioterapia-in-pazienti-con-carcinoma-mammario-a-bassi-livelli-di-espressione-di-her2-con-malattia-ormono-positiva-e-ormono-negativa/ 2022-06-06T09:27:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-anmco-2015-prevenzione-ictus-edoxaban-per-una-terapia-personalizzata-nel-trattamen/ 2016-03-17T16:06:37+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tromboembolismovenoso-per-edoxaban-nuovo-studio-su-pazienti-oncologici/ 2016-05-31T10:48:14+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/leu-approva-lixianar-edoxaban-il-nuovo-anticoagulante-orale-di-daiichi-sankyo/ 2016-05-31T10:47:48+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ricerca-farmaceutica-daiichi-sankyo-premia-i-giovani-talenti-italiani/ 2016-04-25T16:33:41+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-gastrico-her2-positivo-metastatico-o-non-resecabile-nello-studio-di-fase-3-destiny-gastric04-trastuzumab-deruxtecan-ha-ridotto-il-rischio-di-morte-del-30-rispetto-a-ramucirumab-piu-paclitaxel-come-terapia-di-seconda-linea/ 2025-06-03T15:44:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ridere-per-vivere-daiichi-sankyo-italia-a-lezione-dai-clown-dottori/ 2016-04-25T16:32:35+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-metastatico-her2-positivo-trastuzumab-deruxtecan-in-associazione-a-pertuzumab-ha-ridotto-il-rischio-di-progressione-di-malattia-o-di-morte-del-44-rispetto-a-taxano-trastuzumab-e-pertuzumab-thp-come-terapia-di-prima-linea-nello-studio/ 2025-06-03T15:48:41+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-acido-bempedoico-riduce-significativamente-il-rischio-di-eventi-cardiovascolari-maggiori-e-lottimizzazione-delle-terapie-in-associazione-puo-aiutare-piu-pazienti-a-raggiungere-i-target-di-c-ldl/ 2023-05-24T10:39:57+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/san-antonio-breast-cancer-symposium-sabcs-2020-carcinoma-mammario-metastatico-her2-positivo-trastuzumab-deruxtecan-continua-a-mostrare-un-beneficio-significativo-di-durata-della-risposta-tumorale/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2015-combattere-la-fibrillazione-atriale-nel-mondo-reale-partono-in-europa-i-reg/ 2016-05-31T10:47:10+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-del-cuore-2015-danza-e-tai-chi-per-far-star-bene-il-tuo-cuore/ 2016-04-25T16:31:56+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-aha-2017-fibrillazione-atriale-edoxaban-piu-sicuro-del-warfarin-nella-prevenzione-degli/ 2017-11-15T16:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/san-antonio-breast-cancer-symposium-sabcs-2021-cancro-al-seno-triplo-negativo-nuovi-dati-sul-promettente-adc-datopotamab-deruxtecan-confermano-risposta-duratura-e-controllo-della-mallattia/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/sanita-malattie-cardiovascolari-prima-causa-di-morte-in-italia/ 2025-07-15T17:15:07+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-dellictus-2015-prevenzione-e-riduzione-dello-stress-possono-fare-la-differenza/ 2016-04-25T16:31:38+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/battiti-la-musica-col-cuore-cardiologi-e-neurologi-insieme-per-uno-spettacolo-di-musica-e-in/ 2016-04-25T16:31:08+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/world-nutrition-day-2015-piatti-da-chef-per-un-cuore-sano/ 2016-04-25T16:30:45+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-sic-2015/ 2016-05-31T10:46:46+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-mammario-her2-positivo-metastatico-il-chmp-raccomanda-lapprovazione-in-un-ue-di-trastuzumab-deruxtecan/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-her2-metastatico-il-chmp-raccomanda-lapprovazione-in-ue-di-trastuzumab-deruxtecan-per-le-pazienti-trattate-con-un-precedente-regime-a-base-di-anti-her2/ 2022-06-27T11:39:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/la-nuova-terapia-ipolipemizzante-orale-in-tripla-combinazione-per-colmare-le-persistenti-lacune-nella-gestione-del-colesterolo-ldl/ 2025-09-01T09:04:11+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/takamine-awards-2015-ricerca-farmaceutica-dedicato-allo-scopritore-delladrenalina-il-premio-per/ 2016-04-25T16:28:08+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/san-antonio-breast-cancer-symposium-sabcs-2021-tumore-al-seno-her2-ulteriori-analisi-rinforzano-il-rivoluzionario-dato-di-efficacia-di-trastuzumab-deruxtecan-nuovi-dati-del-destiny-breast03-presentati-al-sabcs/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-lancia-la-prima-fan-page-italiana-su-facebook-dedicata-al-paziente-iperteso/ 2016-03-18T07:54:51+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-lipertensione-sono-quasi-18mln-gli-italiani-a-soffrirne-limpegno-global/ 2016-03-18T08:00:35+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/trastuzumab-deruxtecan-ha-dimostrato-risposte-clinicamente-significative-e-durature-in-pazienti-con-diversi-tumori-solidi-avanzati-her2-positivi/ 2023-11-20T12:41:04+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/jan-van-ruymbeke-sara-il-nuovo-ceo-daiichi-sankyo-europa/ 2016-03-18T08:17:53+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ranbaxy-to-extend-daiichi-sankyo-product-reach-to-pharmacists-across-italy-1/ 2016-03-18T09:00:43+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-ash-2017-hokusai-vte-cancer-per-edoxaban-lixiana-efficacia-non-inferiore-alla-daltepa/ 2018-02-13T16:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-in-europa-crea-la-divisione-oncologica-e-rafforza-il-suo-tradiziona/ 2016-03-18T08:20:05+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/joanne-jervis-un-medico-scozzese-al-timone-di-daiichi-sankyo-italia/ 2023-06-12T14:59:45+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/scompenso-cardiaco-accordo-daiichi-sankyo-ge-healthcare-per-il-lancio-in-italia-del-farmaco-ad-uso/ 2016-03-18T09:04:08+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/plexxikon-inc-to-join-daiichi-sankyo-group-1/ 2016-03-18T09:15:55+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-polmone-inizia-la-sperimentazione-di-trastuzumab-deruxtecan-come-terapia-di-prima-linea-per-il-carcinoma-polmonare-non-a-piccole-cellule-metastatico-con-mutazione-her2/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-raised-its-profit-forecast-by-almost-18-1/ 2016-03-18T09:58:40+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-abbattere-il-c-ldl-per-prevenire-infarto-e-ictus-in-un-nuovo-sito-tutto-labc-sul-colesterolo/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/astrazeneca-and-daiichi-sankyo-announce-co-promotion-agreement-for-esomeprazole-nexium-1/ 2016-03-18T09:23:12+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-remains-on-growth-course-in-europe-1/ 2016-03-18T10:07:33+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/per-la-giornata-mondiale-della-donna-un-nuovo-progetto-educativo-da-daiichi-sankyo/ 2016-03-18T10:08:41+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/adesso-losteoporosi-si-cura-ballando/ 2016-03-18T10:10:32+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-cresce-in-europa-e-in-italia/ 2016-03-18T10:13:06+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-premiata-per-il-miglior-portafoglio-prodotti-di-farmaci-cardiovascolari/ 2016-03-18T10:13:59+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-asco-2020-lanticorpo-monoclonale-coniugato-enhertur-trastuzumab-deruxtecan-puo-migliorare-la-prognosi-dei-pazienti-affetti-da-tumore-her2-positivo-o-mutato-i-risultati-presentati-ad-asco20/ 2020-07-14T17:11:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-italia-acquisisce-due-farmaci-cardiovascolari-e-un-team-specializzato-della-merck-ser/ 2016-03-18T10:14:47+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipercolesterolemia-il-chmp-esprime-parere-positivo-per-luso-di-acido-bempedoico-e-dellassociazione-fissa-di-acido-bempedoico-ezetimibe-nel-trattamento-dellipercolesterolemia-per-ridurre-gli-eventi-cardiovascolari/ 2024-03-25T16:05:18+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-annuncia-importanti-risultati-di-fase-3-dello-studio-hokusai-vte-sullefficacia-di/ 2016-03-18T07:56:05+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/nuovi-anticoagulanti-orali-fondamentale-il-ruolo-dei-centri-e-il-networking-con-territorio-e-mmg/ 2019-08-07T15:30:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-i-primi-risultati-dello-studio-europeo-prefer-evidenziano-lurgenza-di-un-s/ 2016-03-18T07:57:20+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/colesterolo-ldl-parte-lo-studio-santorini-di-daiichi-sankyo-per-analizzare-il-trattamento-dellipercolesterolemia-in-europa/ 2020-07-14T17:11:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-mammario-her2-positivo-metastatico-trastuzumab-deruxtecan-approvato-in-ue/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esh-2013-dallo-studio-sevitension-nuove-evidenze-sullefficacia-della-combinazione-fi/ 2016-03-18T07:59:42+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/emilia-romagna-terapia-anticoagulante-promuovere-la-formazione-sui-doac-e-lomogeneizzazione-dei-p/ 2018-02-12T13:53:13+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-e-arqule-annunciano-larruolamento-del-primo-paziente-con-carcinoma-eptacellulare-nel/ 2016-03-18T08:12:39+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-ha-completato-larruolamento-dei-pazienti-per-lo-studio-hokusai-vte-su-edoxaban-il-p/ 2016-03-18T08:13:36+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipertensione-come-prevenirla-e-gestirla-a-tavola-con-il-cardiocooking/ 2016-07-11T17:45:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/edoxaban-demonstrates-superior-efficacy-compared-with-enoxaparin-sodium-in-preventing-vte-after-tota/ 2016-03-18T08:16:05+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-completes-enrollment-of-the-edoxaban-global-phase-iii-engage-af-timi-48-study-1/ 2016-03-18T09:21:32+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/il-tuo-cuore-nelle-tue-mani-parte-da-roma-la-campagna-per-la-prevenzione-cardio-cerebrovascolare-con-screening-gratuiti/ 2025-09-25T10:21:10+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-conferma-il-proprio-impegno-nel-suo-programma-globale-di-ricerca-in-oncologia/ 2016-03-18T10:03:50+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/gli-investimenti-globali-di-daiichi-sankyo-in-ricerca-sviluppo-superano-la-media-del-settore-farma/ 2016-03-18T10:05:05+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-e-in-linea-con-il-piano-di-arruolamento-pazienti-nei-due-maggiori-trial-di-fase-iii/ 2016-03-18T10:06:20+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/combattere-la-fibrillazione-atriale-nel-mondo-reale-terminato-in-europa-larruolamento-di-etna-a/ 2018-02-13T16:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/trastuzumab-deruxtecan-dimostra-un-miglioramento-statisticamente-e-clinicamente-significativo-della-sopravvivenza-libera-da-progressione-nel-tumore-al-seno-metastatico-hr-her2-low-dopo-terapia-endocrina/ 2024-05-02T14:14:00+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/parte-in-europa-il-piu-grande-studio-clinico-di-fase-iii-per-la-prevenzione-e-la-cura-delle-tromboe/ 2016-03-18T10:09:39+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/per-i-pazienti-con-fibrillazione-atriale-sara-piu-agevole-prevenire-lictus-grazie-allanticoa/ 2016-03-18T10:11:56+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-italia-presenta-ampiamente-in-occasione-del-world-inclusion-day/ 2025-10-10T09:24:35+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ipertensione-arrivano-gli-ultimi-dati-clinici-sui-benefici-terapeutici-dellassociazione-triplice/ 2016-03-18T08:58:43+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/sanita-digitale-arriva-il-nuovo-innovation-hub-space-di-daiichi-sankyo-europa-per-migliorare-lassistenza-al-paziente/ 2024-05-27T08:48:34+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/presentati-al-48-congresso-asco-i-risultati-positivi-dello-studio-di-fase-ii-di-tivantinib-in-pazi/ 2016-03-18T08:57:37+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-in-italia-carenza-di-informazione-e-sottoutilizzo-delle-nuove-e-piu-sicure-t/ 2016-07-18T17:07:27+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/carcinoma-mammario-metastatico-her2-positivo-lema-concede-la-valutazione-accelerata-per-trastuzumab-deruxtecan/ 2020-07-14T17:11:01+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/ictus-e-fibrillazione-atriale-a-sud-penalizzati-nellaccesso-alle-nuove-terapie-anticoagulanti/ 2016-07-28T09:32:24+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/lacido-bempedoico-e-la-sua-associazione-a-dose-fissa-con-ezetimibe-approvati-in-europa-anche-per-abbassare-il-colesterolo-e-ridurre-il-rischio-cardiovascolare/ 2024-05-22T16:00:57+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-metastatico-trastuzumab-deruxtecan-migliora-significativamente-sia-la-sopravvivenza-libera-da-progressione-che-quella-globale-nelle-pazienti-con-bassi-livelli-di-her2-i-risultati-dello-studio-destiny-breast04/ 2022-02-22T12:00:50+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/global-phase-iii-trial-with-selective-c-met-inhibitor-tivantinib-arq-197-starts-enrolling-patients-1/ 2016-03-18T09:05:22+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/tumore-al-seno-her2-metastatico-trastuzumab-deruxtecan-approvato-in-ue-per-pazienti-trattati-con-un-precedente-regime-a-base-di-anti-her2/ 2022-08-25T14:43:21+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-and-arqule-enroll-first-non-small-cell-lung-cancer-patient-into-global-phase-iii-tria/ 2016-03-18T09:17:45+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/daiichi-sankyo-announces-first-european-approval-for-sevikar-hctr/ 2016-03-18T09:19:12+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2016-fibrillazione-atriale-rischio-di-ictus-piu-alto-per-i-pazienti-diabetici-trat/ 2016-08-31T09:07:21+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/edoxaban-dimezza-il-rischio-di-tromboembolie-venose-rispetto-a-enoxaparina-dopo-artoplastica-dell/ 2016-03-18T08:59:42+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/congresso-esc-2016-fibrillazione-atriale-edoxaban-lixiana-efficace-e-sicuro-nei-pazienti-affett/ 2016-08-31T09:08:22+02:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-il-cancro-convivere-con-il-cancro-il-progetto-pink-positive-diventa-un-sito-con-nuovi-capitoli-link-utili-e-interviste-agli-esperti/ 2022-01-06T11:45:01+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/giornata-mondiale-contro-la-fibrillazione-atriale-2016-feder-aipa-e-daiichi-sankyo-di-nuovo-in-piaz/ 2016-12-13T17:10:52+01:00 0.5 https://www.daiichi-sankyo.it/media/notizie-in-europa/news-details/fibrillazione-atriale-e-tev-da-oggi-lanticoagulante-orale-edoxaban-prescrivibile-anche-in-italia/ 2016-09-09T09:15:01+02:00 0.5